Crusader Resources (CAS)
Crusader Resources Limited is a specialised minerals exploration company focussed on advancing its wholly owned core gold projects in Brazil across the project exploration and development curve.
Over 130,000 metres of drilling has been completed over these projects, with almost 3 million ounces of resources discovered, 2.4 million ounces at Borborema, a key project in the group. An open pit gold project with strong economics, the Company is focussed on advancing Borborema through BFS and towards a construction decision.
Diversity and exciting prospectivity comes from our Juruena and Nova Astro assets, where there is potential to identify economic and significant ore bodies in a gold district that is attracting interest from major mining companies.
With over 12 years’ in-country experience, Crusader has forged a reputation in the Brazilian mining community as a company which understands the local environment and can successfully develop projects and deliver results to shareholders.
Impax Asset Management Group (IPX)
Impax offers a range of listed equity, fixed income, smart beta and real asset strategies. All strategies utilise the firm’s specialist expertise in understanding investment opportunities arising from the transition to a more sustainable economy
SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester.
The SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load.
SkinBioTherapeutics is targeting three specific skin healthcare sectors; cosmetics, infection control and eczema. In each of these areas SkinBioTherapeutics plans to exemplify its technology in human studies. The most advanced programme is focused on the application of the Skinbiotix® platform in managing sensitive skin in the cosmetics industry. The business strategy is to partner and outlicense its programmes at proof of concept.